MESO (Mesoblast) Change In Receivables : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Mesoblast Change In Receivables?

Mesoblast's change in receivables for the quarter that ended in Dec. 2024 was $0.00 Mil. It means Mesoblast's Accounts Receivable stayed the same from Sep. 2024 to Dec. 2024 .

Mesoblast's change in receivables for the fiscal year that ended in Jun. 2024 was $-13.98 Mil. It means Mesoblast's Accounts Receivable increased by $13.98 Mil from Jun. 2023 to Jun. 2024 .

Mesoblast's Accounts Receivable for the quarter that ended in Dec. 2024 was $1.46 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Mesoblast's liquidation value for the three months ended in Dec. 2024 was $-141.21 Mil.

Mesoblast Change In Receivables Historical Data

The historical data trend for Mesoblast's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Change In Receivables Chart

Mesoblast Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Change In Receivables

Get a 7-Day Free Trial

0.89

-1.74

0.14

-2.51

-13.98

Mesoblast Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Mesoblast Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Mesoblast (NAS:MESO) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Mesoblast's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1.463	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Mesoblast's accounts receivable are only considered to be worth 75% of book value:

Mesoblast's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	37.656	-	192.056	+	0.75 * 1.463	+	0.5 * 24.194
=	-141.21

Mesoblast Change In Receivables Related Terms

Thank you for viewing the detailed overview of Mesoblast's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Mesoblast Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (NAS:MESO) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

MEOBF:USA LWB:Germany LWB1:Germany MSB:Australia

Address

55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000

Website

https://www.mesoblast.com

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.